Wegovy for Adults 65 and Older: School, Structured Activity, and Daily Movement Considerations

Print or save as PDFOpens the printable symptom log and your print dialog. No sign-up.

Does the Wegovy label require physical activity?

The Wegovy injection indications are written as treatment in combination with a reduced calorie diet and increased physical activity: cardiovascular risk reduction, weight reduction, and noncirrhotic MASH with moderate to advanced fibrosis [1]. The indications name no exercise type or weekly target [1].

The label's adult dosing schedule starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12 and 1.7 mg for weeks 13 to 16, with maintenance from week 17 [1]. The recommended maintenance dose for weight reduction in adults is 2.4 mg (or 1.7 mg), and adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go up to 7.2 mg weekly [1]. A missed dose can be given if the next scheduled dose is more than 2 days away; after 2 or more consecutive missed doses the label says to re-escalate from a lower dose [1].

The label's contraindications are a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and a prior serious hypersensitivity reaction to semaglutide or an excipient [1].

How old were the people in the Wegovy trials?

STEP 1, the trial most often quoted for Wegovy's weight effect, randomised 1,961 adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, and no diabetes, for 68 weeks. Mean weight change was -14.9% with semaglutide 2.4 mg versus -2.4% with placebo, and 50.5% versus 4.9% lost at least 15% of body weight [4]. The pooled safety population behind the label's adverse-reaction table, 2,116 people on Wegovy and 1,261 on placebo, had a mean age of 48 years [1].

SELECT enrolled 17,604 adults aged 45 and over with established cardiovascular disease and a BMI of 27 or higher, followed for a mean of 39.8 months [2]. The composite of cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.5% on semaglutide 2.4 mg versus 8.0% on placebo (hazard ratio 0.80), mean weight fell 9.4% versus 0.9% at week 104, and 16.6% versus 8.2% stopped treatment because of adverse events [2].

The closest age breakdown for a semaglutide population comes from the Ozempic label, a different product approved for type 2 diabetes. In its glycemic trials 23.6% of treated patients were 65 or older and 3.2% were 75 or older; in the SUSTAIN 6 cardiovascular trial 48% were 65 or older and 9.6% were 75 or older. The Ozempic label says no overall differences in safety or efficacy were detected between these patients and younger ones, but greater sensitivity of some older individuals cannot be ruled out [5].

What the label lists that can bear on daily activity

In the pooled 68-week weight-management trials in adults, Wegovy 2.4 mg produced nausea in 44% versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6%, constipation in 24% versus 11%, abdominal pain in 20% versus 10%, headache in 14% versus 10% and fatigue in 11% versus 5% [1]. Any gastrointestinal reaction was reported by 73% versus 47%, severe gastrointestinal reactions by 4.1% versus 0.9%, and 6.8% versus 3.2% stopped treatment because of adverse reactions [1].

Dizziness was reported by 8% versus 4%, hypotension-related reactions by 1.3% versus 0.4% and syncope by 0.8% versus 0.2% [1]. The label also lists a heart-rate increase, with a mean rise of 1 to 4 beats per minute and a rise of 20 beats per minute or more in 26% versus 16%, and says to monitor heart rate at regular intervals [1]. In SELECT, hip or pelvis fractures in women occurred in 1% on semaglutide versus 0.2% on placebo [1].

Kidney injury from volume depletion is listed as well: 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with existing kidney impairment and during dose titration, often after fluid loss from gastrointestinal symptoms [1].

At 7.2 mg, dysesthesia, which the label describes as altered skin sensation such as burning or pain from touch, was reported by 22% on 7.2 mg, 6% on 2.4 mg and 0% on placebo. The label says the rate rises with dose and that 18% of those affected on 7.2 mg had not recovered by the end of the trial [1].

Older-adult nutrition guidance

The ESPEN geriatric nutrition guideline takes a cautious line on weight loss in older people: dietary restrictions should generally be avoided, and weight-reducing diets should be considered only in obese older persons with weight-related health problems, then combined with physical exercise [3]. The same guideline recommends routine malnutrition screening for all older persons and treats all older people as at risk of low-intake dehydration, encouraging adequate fluid intake [3]. The Wegovy label describes acute kidney injury from volume depletion as often following fluid loss from gastrointestinal symptoms [1].

Classes, groups and structured programs

The Wegovy label requires increased physical activity alongside the drug [1], and ESPEN recommends that weight-reducing diets in older adults with weight-related health problems be combined with physical exercise [3]. Neither describes a setting, a format or a weekly target, and neither compares one format with another. The trials cited on this page did not test a class-based program, gym course or supervised group exercise as an add-on to Wegovy.

Medicines and blood sugar during activity

Wegovy delays gastric emptying, and the label advises increased clinical or laboratory monitoring for oral medicines with a narrow therapeutic index or that require clinical monitoring [1]. In an interaction study with the semaglutide tablet, levothyroxine exposure rose 33% (90% CI 1.25 to 1.42) [1]. No clinically significant effect was seen on lisinopril, warfarin, metformin, digoxin, ethinyl estradiol, levonorgestrel, furosemide or rosuvastatin [1].

For anyone on insulin or a sulfonylurea, the label warns of hypoglycemia: in adults with type 2 diabetes and a BMI of 27 or higher, glucose below 54 mg/dL occurred in 6.2% on Wegovy 2.4 mg versus 2.5% on placebo, and the label says to consider reducing the insulin or insulin secretagogue dose when starting [1].

What happens when the drug stops

Semaglutide's half-life is about a week, and the drug stays in the body for roughly 5 to 7 weeks after the last 2.4 mg injection [1]. In the STEP 1 off-treatment extension, 327 participants had lost a mean 17.3% at week 68 and regained 11.6 percentage points by week 120, for a net loss of 5.6% [6]. In STEP 4, adults who continued semaglutide lost a further 7.9% between weeks 20 and 68, while those switched to placebo gained 6.9% [7].